PMH50 THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELFREPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA  by Ascher-Svanum, H et al.
279Abstracts
(i) and 4-page (ii) formats; staff preferred 4-page (ii) and 2-page
(i) formats. Using this, we selected version (ii), 4-page format,
the common preference of both groups. Survey developers
should incorporate end-users to provide insight into format pref-
erences and cognitive processing.
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REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA
DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
Ascher-Svanum H, Zhu B, Faries D, Jiang Q
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: In the treatment of schizophrenia, antiparkin-
sonian agents (APKs) are customarily used to counteract drug-
induced reversible movement disorders such as extrapyramidal
symptoms in order to facilitate adherence to antipsychotic regi-
mens. Unfortunately, in addition to beneﬁcial effects, APKs were
shown to cause other adverse effects such as cognitive impair-
ment. This study prospectively examined the role of APKs in self-
reported medication-related cognitive impairment and akathisia
(subjective or objective restlessness) among patients treated over
a 3-year period in usual care with olanzapine or risperidone.
METHODS: Using data from a 3-year observational study of
schizophrenia, we included olanzapine (N = 372) and risperidone
(N = 229) treated patients who continued on index medication
for at least 1-year post enrollment. Medication use was based 
on medical records. Self-reported medication-related cognitive
impairment and akathisia were assessed with validated instru-
ments. Analysis included mixed models adjusted for covariates.
RESULTS: Utilization rates of APKs were almost twice as high
among risperidone than olanzapine-treated patients (p = 0.001).
When not receiving APKs, akathisia was signiﬁcantly worse for
risperidone than olanzapine-treated patients, and rates of
akathisia were comparable when receiving APKs. However,
when receiving APKs, risperidone-treated patients reported sig-
niﬁcant increases in cognitive impairment compared to olanzap-
ine-treated patients (p = 0.0198). CONCLUSIONS: In this
naturalistic 3-year study, freedom from adjunctive antiparkin-
sonian agents was associated with worse akathsia for risperidone
than olanzapine-treated patients. Moreover, use of antiparkin-
sonian agents was linked to worsening of self-reported cognitive
impairment for risperidone but not for olanzapine-treated
patients. Further studies are needed to examine this 
phenomenon.
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IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE
AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION
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OBJECTIVE: To evaluate the effect of adjunctive risperidone
treatment on quality of life in patients with treatment-resistant
depression (TRD). METHODS: Data from the open-label treat-
ment phase (4–6 weeks) of an international study designed to
evaluate the efﬁcacy, safety, and maintenance effect of risperi-
done augmentation to SSRI-treatment in TRD. Quality of life
was evaluated using the short form of Quality-of-Life Enjoyment
and Satisfaction Questionnaire (Q-LES-Q). Change in Q-LES-Q
from baseline was analyzed by paired t-test. Correlation analy-
ses between MADRS and Q-LES-Q change scores were per-
formed using Pearson method. RESULTS: This analysis included
386 subjects, mean age 47.1. Baseline and endpoint mean (SD)
Q-LES-Q scores were 42.8 (14.6) and 56.0 (18.6), indicating 
an improvement of 13.2 with risperidone augmentation (P <
0.0001). Signiﬁcant improvements were observed as early as day
7 (P < 0.0001). Q-LES-Q item 15, medication satisfaction, was
rated as good or very good by 61% of subjects. Correlation
between Q-LES-Q and MADRS total change scores at endpoint
was -0.6. CONCLUSIONS: These ﬁndings suggest that aug-
mentation with risperidone rapidly and signiﬁcantly improves
quality of life in TRD patients. Consistent with previous work,
the correlation between Q-LES-Q and MADRS indicate a mean-
ingful relationship between quality of life improvement and
symptom relief.
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HOSPITALIZATION RATES DURING COMBINATION THERAPY
WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER
Lazarus A1, Lage MJ2, Pesa JA2
1AstraZeneca, Wilmington, DE, USA; 2AstraZeneca LP, Wilmington,
DE, USA
OBJECTIVE: Investigate the effect of atypical antipsychotics
(quetiapine, risperidone, and olanzapine) in combination with a
mood stabilizer on hospitalization rates for bipolar disorder.
METHOD: From the MEDSTAT MarketScan© medical claims
database (1998–2001), 977 individuals were identiﬁed who had
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